Therapies targeting immune checkpoints in the treatment of non-small cell lung cancer and its clinical implications Küçük hücreli dışı akciğer kanseri tedavisinde İmmünolojik kontrol noktalarını hedefleyen tedaviler ve kliniğe yansımaları

Turna H.

Turkish Journal of Immunology, cilt.2, sa.1, ss.16-19, 2014 (SCI Expanded İndekslerine Giren Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 2 Konu: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.5606/tji.2014.0791
  • Dergi Adı: Turkish Journal of Immunology
  • Sayfa Sayıları: ss.16-19


© 2014 Turkish Journal of Immunology.All rights reserved.Although the idea of immunotherapy dates back to 100 years ago, the past two decades witnessed the development of a clinically effective immunotherapy modality for lung cancer, particularly. Clinical implication researches in lung cancer rooted from immunotherapeutic practices for the treatment of melanoma. One of the main treatments of non-small cell lung cancer (NSCLC) is the monoclonal antibody administration to CTLA-4 molecule. The inhibition of CTLA-4, a key mechanism for the inhibition of T-lymphocyte responses, leads to an increased immune anti-tumor response. Similarly, the anti-programmed death-1 (PD-1) molecule antibody therapy dramatically increased the anti-lung cancer cell response in NSCLC patients. The Phase I study of anti-PD-1 antibody showed promising clinical results. Also, there is a strong expectation for the possible effective results of planned and ongoing phase II and phase III studies and beyond.